Follicle Stimulating Hormone Global Market Report 2024

The follicle stimulating hormone market size has grown strongly in recent years. It will grow from $1.94 billion in 2023 to $2.05 billion in 2024 at a compound annual growth rate (CAGR) of 5.7%. The growth observed in the historic period can be linked to a rise in the occurrence of hormonal disorders, an increased need for fertility treatment, the broadening of FSH indications, the introduction of new FSH products to the market, and an escalating demand for secure and efficient contraceptive alternatives.

The follicle stimulating hormone market size is expected to see steady growth in the next few years. It will grow to $2.49 billion in 2028 at a compound annual growth rate (CAGR) of 5.0%. The anticipated growth in the forecast period can be ascribed to the broadening of therapeutic applications, an increasing demand for combination therapy, a rising need for effective contraceptive options, the aging population and its associated healthcare requirements, and the expansion of the market in key regions. Major trends expected in the forecast period include the development of advanced biosimilar FSH products, regulatory approvals and market access, technological advancements in FSH production and delivery, and an increasing demand for effective contraceptive options.

The anticipated growth in the follicle-stimulating hormone market is expected to be propelled by the increasing prevalence of infertility. Infertility, a condition impacting the male or female reproductive system, is characterized by the inability to conceive after 12 months or more of frequent, unprotected sexual contact. Follicle-stimulating hormone plays a crucial role in encouraging egg development in the ovaries and regulating the menstrual cycle in females. In men, it promotes testicular growth and assists in the production of a protein essential for male fertility by supporting the development of healthy sperm cells. Notably, as of April 2023, the World Health Organization reported that infertility affected approximately 1 in 6 adults globally, accounting for around 17.5% of the adult population. Moreover, data from the Australian Bureau of Statistics in October 2023 indicated a 3% decrease in recorded births in 2022, with an overall fertility rate of 1.63 births per woman. Consequently, the increasing prevalence of infertility is a driving force behind the growth of the follicle-stimulating hormone market.

The rising adoption of assisted reproductive technology is also anticipated to contribute to the growth of the follicle-stimulating hormone market in the foreseeable future. Assisted Reproductive Technology (ART) encompasses medical procedures or practices designed to assist individuals or couples in conceiving when conventional methods prove ineffective. The use of follicle-stimulating hormone in assisted reproductive technology is a well-established therapy aimed at enhancing the chances of a successful pregnancy for individuals or couples facing reproductive challenges. Notably, the CDC’s 2021 Fertility Clinic Success Rates Report, released by the Centers for Disease Control and Prevention in September 2023, revealed that approximately 238,126 individuals underwent 413,776 ART cycles at 453 registered clinics in the United States in 2021. These procedures resulted in 91,906 live births and 97,128 live-born infants. Therefore, the increasing adoption of assisted reproductive technology is a key driver for the follicle-stimulating hormone market.


Product innovations emerge as a prominent trend gaining traction in the follicle-stimulating hormone market. Major players in the market are strategically focusing on the development of innovative products to fortify their positions. For example, in August 2021, Merck Specialties Pvt. Ltd., a healthcare company based in India, introduced the Pergoveris Pen as part of efforts to enhance infertility treatment options. The Pergoveris Pen stands out as an innovative device that integrates recombinant follicle-stimulating hormone (FSH) and recombinant luteinizing hormone (LH) in a convenient, pre-filled format. Notably, it is the first pen injector to combine these hormones. Tailored for prescribed use by in vitro fertilization (IVF) specialists, the Pergoveris Pen provides a combination treatment solution specifically designed for women experiencing severe deficiencies in FSH and LH.

Major companies in the follicle-stimulating hormone market are also investing in the development of groundbreaking products such as estrogen-based pills to augment their product offerings and gain a competitive edge. Estrogen-based pills, containing the essential hormone for the growth and management of the female reproductive system, represent a notable innovation. In August 2022, Myovant Sciences Ltd., a UK-based biopharmaceutical company, and Pfizer Inc., a US-based pharmaceutical and biotechnology firm, announced the US Food and Drug Administration (FDA) authorization for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg) as a one-pill treatment. MYFEMBREE serves as a once-daily medication for the treatment of moderate to severe pain caused by endometriosis in premenopausal women for up to 24 months. Additionally, it is authorized for premenopausal women experiencing excessive menstrual bleeding due to uterine fibroids. Myovant and Pfizer intend to jointly market MYFEMBREE in the United States.

In November 2021, Organon, a healthcare company based in the United States, completed the acquisition of Forendo Pharma, a clinical-stage drug development company based in Finland, for an undisclosed amount. This acquisition is expected to enhance Organon's portfolio of women's health treatments, particularly in the domain of follicle-stimulating hormones.

Major companies operating in the follicle stimulating hormone market report are Pfizer Inc., Novartis AG, Abbott Laboratories, Sanofi S.A., Boehringer Ingelheim GmbH, Merck KGaA, Teva Pharmaceutical Industries Ltd., Sun Pharmaceutical Industries Ltd., Intas Pharmaceuticals Ltd., Cipla Ltd., Ferring Pharmaceuticals Inc., Lupin Limited, Zydus Lifesciences Limited, Livzon Pharmaceutical Group Inc., Emcure Pharmaceuticals Ltd., LG Chem's life sciences, IBSA Group, Bharat Serums and Vaccines Limited, Nihon Kohden Corp., Anhui Anke Biotechnology Group Co. Ltd., Taj Pharmaceuticals Ltd., Genpharm Inc., Cadwell Laboratories Inc., Creative BioMart, Electrical Geodesics Inc., Lee Biosolutions Inc., Trumac Healthcare, Midas Pharma GmbH, Biogenix Inc. Pvt. Ltd., Shanghai Techwell Biopharmaceutical Co. Ltd.

North America was the largest region in the follicle stimulating hormone market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the follicle stimulating hormone market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the follicle stimulating hormone market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Italy, Spain, Canada.

The primary types of follicle-stimulating hormones include recombinant FSH and urinary FSH. Recombinant FSH is a form of FSH produced using recombinant DNA technology, as opposed to being derived from natural sources such as urine. These hormones find application in various areas, including infertility treatment, assisted reproductive technology (ART), and other medical contexts. They are utilized by diverse end-users, including infertility centers, hospitals, and similar institutions.

The follicle stimulating hormone market research report is one of a series of new reports that provides follicle stimulating hormone market statistics, including follicle stimulating hormone industry global market size, regional shares, competitors with a follicle stimulating hormone market share, detailed follicle stimulating hormone market segments, market trends and opportunities, and any further data you may need to thrive in the follicle stimulating hormone industry. This follicle stimulating hormone market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The follicle-stimulating hormone market consists of sales of luteinizing hormone (LH), chorionic gonadotropin (CG), and thyroid-stimulating hormone. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.


The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).


The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.